CNTX – context therapeutics inc. (US:NASDAQ)
Stock Stats
News
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 [Yahoo! Finance]
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Form 8-K Context Therapeutics For: Apr 09
Form PRE 14A Context Therapeutics For: Jun 12
Form S-8 Context Therapeutics
Form 10-K Context Therapeutics For: Dec 31
Form 8-K Context Therapeutics For: Feb 27
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.